马蒂·马卡里博士：美国与中国在研发冠状病毒疫苗的竞赛中"齐头并进"

约翰霍普金斯大学卫生政策与管理学教授马蒂·马卡里博士周三说，美国与中国在研发有效的冠状病毒疫苗竞赛中正在"齐头并进"。

马卡里说："有70种疫苗处于不同的研发阶段。现在有七种疫苗正在让患者服用。我们与中国可以说是齐头并进——我们有三个，他们有三个。"

马卡里补充说，中国的疫苗"实际上处于先发阶段"。他们的药物研发处于第二或第三阶段，这是一个真正的竞赛...抢先到达那里的国家将具有显著的优势，因为它们将控制世界其它地区的供应，而由此带来的风险在于，如果我们不抢先到达那里，我们可能会被关在门外。"

教授总结说，对疫苗的探索正在"向前推进"，但他补充说，"可能需要一年"才能广泛应用这种疗法。"

周三早些时候，政府顶级传染病专家、特朗普总统冠状病毒特别工作组成员安东尼·福奇博士吹嘘说，新数据反馈表明瑞德西韦药物"在减少恢复时间方面有显著的积极作用"。

马卡里说，虽然国家卫生研究院的研究表明，恢复时间的降低率只有31%，但可能证明是显著的。

"有一件事要记住，"马卡里在提及瑞德西韦时告诫说，"这不是一颗银弹。"它降低了严重程度，并可能加快恢复时间，但同时，这是静脉注射药物，它不是你今晚可以去药房去随便拿的东西。

瑞德西韦作为冠状病毒治疗药物仍在等待美国的监管批准，但马卡里说，它很可能获得美国食品和药物管理局的紧急授权，"最早在今晚"。

Dr. Marty Makary: US is 'neck-and-neck'with China in race for coronavirus vaccine

The United States is"neck-and-neck" with China in the race to develop an effective coronavirusvaccine, Johns Hopkins University health policy and management professor Dr.Marty Makary said Wednesday.

"There are 70 vaccines in differentstages of development," said Makary. "There are seven that are beinggiven in patients right now. We’re sort of neck-and-neck with China --we've got three, they've got three."

Makary added that the Chinese vaccines"are actually in further stages [of development]. Their drugs are inphase two or three, and it's a real race ...The country that getsthere first will have a significant advantage because theywill control the supply for the rest of the world and the risk isif we aren't there first, we could get locked out."

The professor concluded that the search fora vaccine was "moving along," but added that "it will probablytake a year" before such a treatment becomes widely available.

Earlier Wednesday, Dr. Anthony Fauci, thegovernment's top infectious-disease expert and a member of President Trump'scoronavirus task force, touted the drug remdesivir for its"clear-cut significant positive effect in diminishing the time torecovery,” as reflected in new data.

Makary said that while the NationalInstitutes of Health study shows only a 31 percent reduction rate in recoverytime, it could prove to be significant.

"One thing to remember,"Makary cautioned about remdesivir, "it's not a silver bullet."It reduces the severity and probably increases recoverybut also, this is an IV medication, it's not something you cango to the pharmacy tonight and pick up."

In the U.S., remdesivir is still awaitingregulatory approval as a coronavirus treatment, but Makary said it is likely toreceive emergency authorization from the Food and DrugAdministration "as early as this evening."